Intellectual Property
Intellectual Property
At the heart of Ractigen Therapeutics lies a strong intellectual property (IP) foundation, notably in the fields of RNA activation (RNAa) and oligonucleotide delivery. Central to our innovation is a high-throughput discovery engine, expertly designed for the swift identification of small activating RNAs (saRNAs). Our IP portfolio is strategically constructed upon both the composition of matter and methods of use, encompassing an expanding library of therapeutic oligonucleotides. The development of proprietary medicinal chemistries and delivery platforms, all created in-house, further solidifies our IP estate, providing a robust platform for advanced drug development
High-Throughput
Process
Our Discovery Engine
It features a highly-refined bioinformatics algorithm integrating epigenetic datasets, design rules, and genome-wide on-target prediction tethered to in-house oligonucleotide manufacturing for saRNA synthesis followed by automated experimental validation of saRNA activity.
Target Gene Locus
Rapidly identify all saRNAs for any single target gene
Search Algorithm
Highly-refined
bioinformatics algorithm
In-House Synthesis
Oligonucleotide manufacturing for in-house saRNA synthesis
In vitro Screening & Gene Expression
Automated rounds of dose-dependent gene expression
3-4 Weeks Start to Finish (All In-House)
Screen Hundreds of saRNA Candidates
Automated rounds of dose-dependent gene expression analytics and integrated de-risking safety assays allow for the screening of hundreds of saRNA candidates within 30-45 days.
Honing the Process
We are continually honing the process in pursuit of full-automation and continue to add to our ever-growing list of therapeutic genes expanding our IP estate and feeding our drug development pipeline.
Want to Discover More?
Check out our News. Below are some highlights to get you started.
Ractigen’s RAG-17 ALS Data Shines at AAN 2025: Earns Top Award, Phase I Advances
Final results from an Investigator-Initiated Trial presented for the first time, demonstrating favorable safety, significant…
Read More
RAG-17, a Novel siRNA Therapy for SOD1-ALS: Safety and Preliminary Efficacy from a First-in-human Trial (Abstract)
Event: American Academy of Neurology (AAN) 2025 Annual Meeting (San Diego) View Abstract View News:…
Read More
